Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

Comment by jopatcloon May 26, 2024 8:43am
60 Views
Post# 36057815

RE:RE:RE:RE:Collaboration is key to making this vision a reality.

RE:RE:RE:RE:Collaboration is key to making this vision a reality.Very good DD on Mayo Clinic THANKS
 

ARTIFICIAL INTELLIGENCE

AI at the Mayo Clinic: The leading edge of curating data and building apps

BY JERRY ZEIDENBERG

April 30, 2024


ORLANDO, FLA. – We know that the usefulness of AI-driven solutions is tied to both the quality and quantity of the data used. It’s not just a matter of garbage in, garbage out. You’ve got to have a massive amount of high-quality data to train the algorithms – that’s how to get results that will work with a broad range of patients. For this reason, the Mayo Clinic is building one of the largest repositories of clinical data in the world.

 

“Everything starts with data,” asserted Dr. John Halamka, president of the Mayo Clinic Platform, which is focused on transforming healthcare through the use of AI, connected devices and a network of partners.

He explained in a presentation at the recent HIMSS conference that you need accurate data and a lot of it. A colleague at another organization told him that his facility had 5,000 patient records with which they will build AI algorithms. “That’s not enough breadth,” warned Halamka.

For its part, the Mayo Clinic has 11.2 million patients with electronic records. And it’s not stopping there. The hospital chain is building a global, federated network of partner hospitals and patient records that can be drawn upon for building apps.

Already, it has 242 algorithms under development. The goal is to improve the art and science of medicine around the world.

“You need a global network to deliver on a global basis,” said Halamka. So, the Mayo Clinic has been creating alliances with other large hospitals and health organizations to share data. They include Toronto’s University Health Network, along with the Apollo chain of 73 hospitals in India and the Albert Einstein hospital in Brazil.

The data are de-identified and they never actually leave the host site – instead, metrics about the anonymous patients are shared.

That protects patient privacy. And the sharing of data over a wide range of geographies and ethnicities helps avoid bias in the data, as much as possible, when building AI models.

Nevertheless, said Halamka, “every algorithm will have a bias. We create and test the algorithms, recognize the bias, and then adjust.”


<< Previous
Bullboard Posts
Next >>